Archive | November, 2016

Happy Thanksgiving and Warm Wishes from LSN

24 Nov

By Dennis Ford, Founder & CEO, LSN

LSN would like to wish you all a happy Thanksgiving. We are thankful for your support and engagement on our path to build connections between early stage life science technologies and investors. We wish you all the greatest success in building your respective buinesses and moving new treatments to market.

As is LSN’s Thanksgiving tradition, we’re serving up the 10 most recent life science investment mandates gathered by LSN Research. These mandates show the breadth of coverage that LSN has among life science investors, with investors including international PE firms, expert regional investors, and global pharma firms. If one of these investors is a fit for your opportunity, we’d love to hear from you.

While you enjoy the spread on your own tables at home, click the mandates below to see what the LSN Investor Platform is serving up:

1. PE Firm Raises New Fund for Early Stage & Growth Stage Medtech Opportunities

2. New VC Firm Seeks Medtech, Diagnostics and Digital Health Deals in Europe

3. Pharma Firm Invests in Therapeutic Assets in Oncology, Autoimmune, Diabetes and Infectious Disease

4. Venture Development Organization Invests in Life Science Startups in Ohio

5. Sovereign Wealth Fund Looks Globally for Life Science Deals

6. Diagnostics Firm Seeks Early Stage Partnerships

7. China-based Venture Firm Seeks Healthcare IT for China Market

8. Seed Stage Angel Fund Seeks Devices in North Carolina

9. Large Pharma Firm Focuses on Oncology, Women’s Health, Cardiology and Diagnostics

10. European VC Invests in Therapeutics and Medtech in the Benelux Region

Hot Investor Mandate 1: PE Firm Raises New Fund for Early Stage & Growth Stage Medtech Opportunities

24 Nov

A private equity investment firm based in Israel is investing from a new fund that aims to close at $300M. For early-stage companies, the firm typically invests from few $100K to a couple million per company; for platforms/late stage, the firm usually invest up to $25M per company; and may syndicate for more capital if required. The firm invests in two platform deals and one early-stage company per year. The firm is interested in companies based in the U.S., Europe, or Israel.

The firm is interested in medical devices only. The firm is agnostic to disease indication and is not interested in pharmaceuticals. Accelmed may be interested in the diagnostics and digital health space, though is quite selective in these opportunities. For early-stage opportunities, the firm is interested in disruptive technologies at IP and/or preclinical stage. In the past, the firm has invested in cardiology and diabetes, and is currently looking at neurology; the firm is also open to new areas of focus. For late-stage/Platform companies, the firm is interested in those that have sales between $30-70M as well as sales organization in different fields within the company’s space.

For early stage investment, the firm does not have a management team requirement, as it has the capability to invest in technology and IP alone and build the team around it. The firm is very active post investment by taking more than just a board seat, the firm gets very involved in the company formation and development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 2: New VC Firm Seeks Medtech, Diagnostics and Digital Health Deals in Europe

24 Nov

A new venture capital fund based in Switzerland held its first closing of approximately $30 million in 2016 and plans to have a final closing at $80 million in 2017. The firm looks to make equity investments in seed to later stage companies with initial investments ranging from around $500,000 to $3 million depending on the type and stage of company. The firm also looks to reserve additional capital for follow on financing for each investment. The firm typically looks to lead investment rounds but is also open to co-investing. The firm is currently looking for companies throughout Europe with a preference for those located in Switzerland.

The firm is looking for companies in sectors of medical devices, diagnostics, digital health, and to a lesser extent laboratory equipment. The firm is not interested in traditional biotech or pharma opportunities, only select less capital intensive drug discovery opportunities will be considered. The firm is both technology and indication agnostic, focusing more on opportunities that are not highly capital and time intensive. The firm is looking for companies that are anywhere from the prototype stage to those that have a product on the market. The firm also places significant importance on companies that can provide a clear health economic benefit to both the patients and their healthcare providers.

The firm looks for companies with driven, energetic management teams and strongly prefers companies whose management teams have (or are about to seek) complementary skills in sales, marketing, product development, as well as technical and scientific expertise. The firm is only interested in privately held companies. The firm looks to take a board seat following investment and takes a very active role in helping companies grow, leveraging both internal expertise as well as their deep external network. The firm is looking for companies that have a clear and defined business plan and is not interested in late stage research projects.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 3: Pharma Firm Invests in Therapeutic Assets in Oncology, Autoimmune, Diabetes and Infectious Disease

24 Nov

A large pharmaceutical firm based in China is currently seeking innovations in therapeutics field. The firm is open to collaborative research, licensing, equity investment and M&A opportunities. The firm has no set limit regarding the size of investment. The firm considers opportunities from across the world.

The firm considers oncology, autoimmune, diabetes, and infectious diseases. Within oncology, the firm focuses on gastric, breast, and liver cancer. The firm is open to all modalities of therapeutics and is opportunistic in terms of stage of development.

The firm is seeking competent management teams with strong sector expertise. The firm may request regional rights on a case-by-case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 4: Venture Development Organization Invests in Life Science Startups in Ohio

24 Nov

A venture development organization provides capital, a range of services and network connections to early-stage companies in the life science space and beyond. The firm invests out of several funds, with a combined $60M under management. The firm is mainly focused on early-stage companies (concept, seed or seed+/ early stage) and therefore, typically makes investments ranging $100K-$1M. The firm usually makes about 20 investments per year, with about 25% of these made in life science companies. Convertible notes are preferred for smaller investments in earlier stage companies, with equity investments reserved for larger, more mature deals. The firm only considers companies headquartered in the central Ohio area.

The firm is open to most sectors including therapeutics, medical devices and healthcare IT. The firm is indication agnostic, and evaluates opportunities relative to the markets they are entering. The firm is most interested in products that are in the pre-clinical phase of development, although the firm has invested in some Phase I therapeutic assets and marketed medical devices. The firm has invested in companies developing a range of different products including an advanced healthcare analytics platform, a gene-therapy therapeutic and a cell-culture products platform technology.

Given the nature of the organization, the firm has no management team requirements and will work with entrepreneurs of all experience levels. A board seat is usually only required along with larger investments, and can be filled by a member of the firm’s investment team or one of their partners.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 5: Sovereign Wealth Fund Looks Globally for Life Science Deals

24 Nov

An Life Science focused private equity and venture capital firm affiliated with a sovereign wealth fund maintains an evergreen investment fund and generally makes longer term investments than a typical VC. The firm does not make seed investments, but is interested in both early stage venture capital investments and late stage companies seeking growth and expansion capital. Typically, the firm invests USD 5-15 million per opportunity. The firm can invest globally and is actively seeking new investment opportunities.

The firm seeks to invest in breakthrough healthcare biotech, medical devices, diagnostics, healthcare IT, and biorenewable and bioindustrial technologies. The firm is open to a wide range of technologies including novel techniques such as stem cells and genomics, and will consider investing in any area of medicine. The firm prefers to invest in technologies that have attained clinical validation.

The firm seeks a strong and experienced management team. The firm may take a board seat on a case by case basis.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Investor Mandate 6: Diagnostics Firm Seeks Early Stage Partnerships

24 Nov

A major diagnostics firm conducts global business development and licensing in early stage diagnostic and sequencing technologies. The firm employs a variety of deal structures including IP rights, co-development, partnerships, and M&A.

The firm is interested in new technologies in point of care diagnostics, molecular diagnostics, tissue diagnostics, bioinformatics, and instrumentation, sequencing and associated software. The firm’s indications of interest include oncology, sepsis, pre-natal health and women’s health, bone metabolism, cardiovascular disease, diabetes and metabolic disease, kidney disease, infectious disease, and genetic disorders.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com